Integrated Biopharma

Integrated Biopharma OCF Margin

The Operating Cash Flow Margin of Integrated Biopharma (INBP) as of Oct 9, 2026 is 3.80 %. In the previous year, Operating Cash Flow Margin was 1.87 % — a change of 102.72% (higher).

OCF Margin

3.80 %

YoY

102.72%

Last updated:

Operating Cash Flow Margin of Integrated Biopharma is 2025 3.80 % . Operating Cash Flow Margin of Integrated Biopharma was 2024 1.87 % . It decreases by 102.72% higher compared to the previous year.

The Integrated Biopharma OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
2.67 USD
Jan 1, 2019
0.66 USD
Jan 1, 2020
2.54 USD
Jan 1, 2021
4.80 USD
Jan 1, 2022
7.27 USD
Jan 1, 2023
2.43 USD
Jan 1, 2024
1.87 USD
Jan 1, 2025
3.80 USD
The Integrated Biopharma OCF Margin history
YEAROCF MarginYoY
3.80 %+102.72%
1.87 %-22.92%
2.43 %-66.57%
7.27 %+51.57%
4.80 %+89.11%
2.54 %+286.63%
0.66 %-75.44%
2.67 %+216.04%
0.85 %-160.09%
-1.41 %+366.81%
-0.30 %-105.41%
5.57 %—
Access this data via the Eulerpool API

Integrated Biopharma Stock analysis

What does Integrated Biopharma do? Integrated Biopharma Inc. is a New York-based company specializing in the development, manufacturing, and marketing of health products. Founded in 1979, the company has acquired extensive experience in the industry. Integrated Biopharma's business activities encompass four main areas: biopharmaceuticals, pharmaceuticals, dietary supplements, and veterinary products. Each of these divisions is focused on the development and manufacturing of specific products, contributing to the overall business of the company. In the biopharmaceuticals sector, the company focuses on developing therapeutic products for rare and severe diseases. The product development is carried out in close collaboration with the Columbia University Medical School. In the pharmaceuticals sector, Integrated Biopharma produces generics as well as its own products targeting the treatment of diabetes, cancer, and cardiovascular diseases, among others. Dietary supplements are also part of Integrated Biopharma's product portfolio, with a focus on manufacturing vitamin and mineral supplements, as well as herbal dietary supplements. Additionally, the company offers a variety of veterinary products, including preparations for the health of domestic and farm animals, as well as medications for the treatment of animal diseases. One important business model of Integrated Biopharma is the manufacturing and marketing of mostly patent-free, yet high-quality products. Furthermore, the company collaborates closely with other companies and institutions to develop new products and technologies. Another important strategy of Integrated Biopharma is to market its products worldwide. The company has distribution partners in many countries, including China, Canada, Mexico, France, and Germany. Integrated Biopharma places a strong emphasis on the highest quality standards and therefore invests in modern infrastructure and a well-trained workforce. The company operates its own production facilities and research institutions in the USA and China. Among Integrated Biopharma's most well-known products are the diabetes medication "GlipiZIDE," the carcinoma medication "Paclitaxel," and the veterinary antibiotic "Gentamicin Sulfate." Overall, Integrated Biopharma has received numerous awards and certifications for its products and business activities in recent years. The high quality and effectiveness of its preparations, as well as its responsible approach to resources and the environment, make Integrated Biopharma an important player in the healthcare industry. Integrated Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Integrated Biopharma stock

Operating Cash Flow Margin of Integrated Biopharma is 3.80 % in 2025.

Operating Cash Flow Margin of Integrated Biopharma changed from 1.87 % to 3.80 %, representing a 102.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Integrated Biopharma since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Integrated Biopharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

Margins — Integrated Biopharma

All Key Metrics — Integrated Biopharma